{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/53176"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/53176","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"A review of stem cell therapy for Alzheimer’s disease: potential benefits, translational limitations, and future perspectives","abstract":"Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that severely impairs cognitive function, independence, and overall quality of life. As the aging population grows, the societal and economic burden of AD continues to increase. Current treatments focus on symptom management do not stop disease progression or reverse cognitive decline. The limitations of existing pharmacological interventions highlight the need for innovative therapeutic strategies that target the underlying pathology of AD.Stem cell therapy has emerged as a promising approach in the field of neurodegenerative diseases due to its potential to regenerate damaged neural tissue, reduce neuroinflammation, and improve cognitive function. Preclinical studies have shown positive results in restoring memory and synaptic connectivity in AD models. However, despite these advancements, significant translational barriers remain. Issues such as delivery method, optimal cell type, ethical concerns, immune rejection, and long-term safety continue to hinder the integration of stem cell therapy into routine clinical practice. This thesis aims to evaluate the potential benefits of stem cell-based treatments for AD while critically examining the limitations in translating these therapies from bench to bedside. The discussion includes current evidence from human clinical trials, the biological rationale behind various stem cell types, and the public health implications of integrating novel therapies into dementia care. Additionally, future perspectives are offered on how the field can move forward in balancing innovation with safety, accessibility, and ethical responsibility.","abstract_html":"Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that severely impairs cognitive function, independence, and overall quality of life. As the aging population grows, the societal and economic burden of AD continues to increase. Current treatments focus on symptom management do not stop disease progression or reverse cognitive decline. The limitations of existing pharmacological interventions highlight the need for innovative therapeutic strategies that target the underlying pathology of AD.Stem cell therapy has emerged as a promising approach in the field of neurodegenerative diseases due to its potential to regenerate damaged neural tissue, reduce neuroinflammation, and improve cognitive function. Preclinical studies have shown positive results in restoring memory and synaptic connectivity in AD models. However, despite these advancements, significant translational barriers remain. Issues such as delivery method, optimal cell type, ethical concerns, immune rejection, and long-term safety continue to hinder the integration of stem cell therapy into routine clinical practice. This thesis aims to evaluate the potential benefits of stem cell-based treatments for AD while critically examining the limitations in translating these therapies from bench to bedside. The discussion includes current evidence from human clinical trials, the biological rationale behind various stem cell types, and the public health implications of integrating novel therapies into dementia care. Additionally, future perspectives are offered on how the field can move forward in balancing innovation with safety, accessibility, and ethical responsibility.","abstract_has_math":false,"creators":["Jazrawi, Isabella"],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":[],"advisors":["Haydar, Tarik","Devine, Sherral"],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025","date_published":"2025","updated_at":"2026-11-18T19:48:56Z","subjects":["Cellular biology","Biochemistry","Neurosciences","Alzheimer’s disease","Cognitive decline","Neurodegeneration","Regenerative medicine","Stem cell therapy","Translational barriers"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[{"key":"dc:identifier.orcid","label":"ORCID","values":["0009-0005-3278-4967"],"render_values":[{"text":"0009-0005-3278-4967","href":"https://orcid.org/0009-0005-3278-4967","code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2144/53176","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/53176","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F53176","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Haydar, Tarik","Devine, Sherral"]},{"key":"dc:creator","label":"Author","values":["Jazrawi, Isabella"]},{"key":"dc:identifier.orcid","label":"ORCID","values":["0009-0005-3278-4967"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-06-17T18:32:48Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2026-06-17T18:32:48Z"]},{"key":"dc:date.issued","label":"Date","values":["2025"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2026-06-17T16:05:47Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Cellular biology","Biochemistry","Neurosciences","Alzheimer’s disease","Cognitive decline","Neurodegeneration","Regenerative medicine","Stem cell therapy","Translational barriers"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/53176"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2025"]},{"key":"dc:description.abstract","label":"Abstract","values":["Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that severely impairs cognitive function, independence, and overall quality of life. As the aging population grows, the societal and economic burden of AD continues to increase. Current treatments focus on symptom management do not stop disease progression or reverse cognitive decline. The limitations of existing pharmacological interventions highlight the need for innovative therapeutic strategies that target the underlying pathology of AD.Stem cell therapy has emerged as a promising approach in the field of neurodegenerative diseases due to its potential to regenerate damaged neural tissue, reduce neuroinflammation, and improve cognitive function. Preclinical studies have shown positive results in restoring memory and synaptic connectivity in AD models. However, despite these advancements, significant translational barriers remain. Issues such as delivery method, optimal cell type, ethical concerns, immune rejection, and long-term safety continue to hinder the integration of stem cell therapy into routine clinical practice. This thesis aims to evaluate the potential benefits of stem cell-based treatments for AD while critically examining the limitations in translating these therapies from bench to bedside. The discussion includes current evidence from human clinical trials, the biological rationale behind various stem cell types, and the public health implications of integrating novel therapies into dementia care. Additionally, future perspectives are offered on how the field can move forward in balancing innovation with safety, accessibility, and ethical responsibility."]},{"key":"dc:title","label":"Title","values":["A review of stem cell therapy for Alzheimer’s disease: potential benefits, translational limitations, and future perspectives"]}]}],"canonical_facts":{"dc:contributor.advisor":["Haydar, Tarik","Devine, Sherral"],"dc:creator":["Jazrawi, Isabella"],"dc:date.accessioned":["2026-06-17T18:32:48Z"],"dc:date.available":["2026-06-17T18:32:48Z"],"dc:date.issued":["2025"],"dc:date.updated":["2026-06-17T16:05:47Z"],"dc:description":["2025"],"dc:description.abstract":["Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that severely impairs cognitive function, independence, and overall quality of life. As the aging population grows, the societal and economic burden of AD continues to increase. Current treatments focus on symptom management do not stop disease progression or reverse cognitive decline. The limitations of existing pharmacological interventions highlight the need for innovative therapeutic strategies that target the underlying pathology of AD.Stem cell therapy has emerged as a promising approach in the field of neurodegenerative diseases due to its potential to regenerate damaged neural tissue, reduce neuroinflammation, and improve cognitive function. Preclinical studies have shown positive results in restoring memory and synaptic connectivity in AD models. However, despite these advancements, significant translational barriers remain. Issues such as delivery method, optimal cell type, ethical concerns, immune rejection, and long-term safety continue to hinder the integration of stem cell therapy into routine clinical practice. This thesis aims to evaluate the potential benefits of stem cell-based treatments for AD while critically examining the limitations in translating these therapies from bench to bedside. The discussion includes current evidence from human clinical trials, the biological rationale behind various stem cell types, and the public health implications of integrating novel therapies into dementia care. Additionally, future perspectives are offered on how the field can move forward in balancing innovation with safety, accessibility, and ethical responsibility."],"dc:identifier.orcid":["0009-0005-3278-4967"],"dc:identifier.uri":["https://hdl.handle.net/2144/53176"],"dc:language.iso":["en_US"],"dc:subject":["Cellular biology","Biochemistry","Neurosciences","Alzheimer’s disease","Cognitive decline","Neurodegeneration","Regenerative medicine","Stem cell therapy","Translational barriers"],"dc:title":["A review of stem cell therapy for Alzheimer’s disease: potential benefits, translational limitations, and future perspectives"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T19:48:56Z"}